USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
RADIX THERAPEUTICS, LLC
Address:
1125 TALLOW DR
DICKINSON, TX
Phone:
N/A
URL:
N/A
EIN:
126447879
DUNS:
829971899
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $497,083.00 2
STTR Phase I $300,000.00 1

Award List:

TP508:A New Drug for Mitigating Lethal Effects of Radiation Exposure

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$297,326.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): With increasing risk of nuclear detonation there is a need for effective medicinal counter-measures that can be delivered after exposure to prevent radiation-induced mortality. Adding to this need, mortality increases s ignificantly when radiation is combined… More

Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Randall M. Goldblum – 409-772-1750
Research Institution:
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Up to 30% of the US population are now affected by nasal allergy, resulting in a total (direct and indirect) cost of approximately 14.6 billion per year. Seasonal allergic rhinitis (AR), due to exposure to airborne pollen and molds is a major component of this… More

TAS::75 0849::TAS

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$199,757.00
Agency:
HHS
Principal Investigator:
Barbara Olszewska-pazdrak – 281-352-5249
Abstract:
Over 60% of cancer patients are treated with radiotherapy, yet radiation-induced normal tissue damage can cause organ dysfunction and morbidity. Radiotherapy of CNS tumors is problematic due to potential for diminished neurological function or mental retardation. Our proprietary thrombin-derived… More